However, none of the PDE4 inhibitors tested so far has reached the market, mainly owing to tolerability issues such as emesis. A study in Nature Biotechnology that sheds light on the structural ...

Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without ...

In a new study, researchers found that a PDE4 inhibitor increased salivation because of PDE4 inhibition in the salivary glands and in the autonomic nervous system, which regulates involuntary body ...

PALI-2108 is an orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug being developed for ulcerative colitis patients. Preclinical studies indicated that PALI-2108 ...

Roflumilast (ALTANA Pharma AG), a phosphodiesterase-4 (PDE4) inhibitor, is being developed for the management of chronic obstructive pulmonary disease (COPD) and asthma. Its once-daily oral ...

The application of PDE4 inhibitors appears to be a promising option to facilitate with minimal side effects the spontaneous passage of (distal) ureteral stones and relieve pain associated with ...

In a challenging market environment, PALI Pharmaceuticals' stock has tumbled to a 52-week low, with shares dropping to a price level of 1.15 USD. According to InvestingPro data, the company maintains ...

Other oral therapies for this are already available; notably, Amgen’s PDE4 inhibitor Otezla (apremilast) and Bristol Myers Squibb’s Tyk-2 inhibitor Sotyktu (deucravacitinib). So, Dice’s lead ...

Crucially, it extends the label for the PDE 4 inhibitor to include people with mild psoriasis, unlocking a sizeable new market for the drug, which has been approved since 2014 for moderate to ...

Nuance Pharma ("Nuance") announced that the Pharmaceutical Administration Bureau Macau approved Ohtuvayre™ (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) ...